SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

I don't know about the rest of you,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
pphmtoolong Member Profile
 
Followed By 26
Posts 3,644
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 9/19/2017 2:51:59 PM
Avid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition "GlobeNewswire Inc." - 9/19/2017 8:05:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/14/2017 5:21:37 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 9/14/2017 5:19:50 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 9/11/2017 5:14:45 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 5:04:28 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 9/11/2017 5:02:13 PM
Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments "GlobeNewswire Inc." - 9/11/2017 4:05:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 3:37:19 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 9/11/2017 3:35:34 PM
Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices "GlobeNewswire Inc." - 9/11/2017 8:05:00 AM
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combinati... "GlobeNewswire Inc." - 9/7/2017 8:10:00 AM
Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017 "GlobeNewswire Inc." - 9/6/2017 4:05:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/5/2017 4:31:30 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 9/5/2017 4:05:00 PM
Proxy Statement - Contested Solicitations (preliminary) (prec14a) "Edgar (US Regulatory)" - 8/29/2017 5:23:59 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/29/2017 5:18:13 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/29/2017 5:17:43 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/29/2017 5:17:43 PM
Amended Annual Report (10-k/a) "Edgar (US Regulatory)" - 8/28/2017 4:57:00 PM
Avid Bioservices to Exhibit at The Bioprocessing Summit 2017 "GlobeNewswire Inc." - 8/16/2017 8:05:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) "Edgar (US Regulatory)" - 8/14/2017 2:58:31 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 8/14/2017 2:45:29 PM
Ronin Trading and SW Investment Management Respond to Recent Announcements by Peregrine Pharmaceuticals "PR Newswire (US)" - 8/14/2017 9:01:00 AM
pphmtoolong   Tuesday, 04/24/12 10:44:52 AM
Re: None
Post # of 312603 
I don't know about the rest of you, but I bought this stock based on Thorpe's approved patents and the early Bavi clinical studies.

It seems that Peregrine management and BOD have done everything reasonable to forward the Bavi agenda given the limited financial resources available. Running the trials overseas in Georgia and India could not have been easy, but they did it and got promising results. As in many other cases Bavi may not pan out in later stage trials. I don't blame management for trying with Bavi, and I don't blame management for the perversity of Mother Nature. I could blame them for excessive optimism, but the science seemed sound to them just as it seemed sound to us.

I don't like that managment has diluted the heck out of our stock, but I really don't buy any of the alternative financing plans I've seen presented here. I am a retired CPA; so I have some confidence assessment on this point.

If Bavi finally hits it out of the park with second line NSCLC, there is still a chance for us to make money. Otherwise, this has been a very expensive lesson in wishful thinking on biotechs. I blame only myself if Peregrine flops. I never should have thrown so much money into such a crap shoot.

Paul


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist